Market Closed -
Nasdaq
04:30:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
2.1
USD
|
+1.44%
|
|
-14.99%
|
-48.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
78.76
|
698.4
|
198.5
|
41.44
|
42.17
|
26.14
|
-
|
-
|
Enterprise Value (EV)
1 |
78.76
|
698.4
|
198.5
|
41.44
|
42.17
|
26.14
|
26.14
|
26.14
|
P/E ratio
|
-4.5
x
|
-37.3
x
|
-6.32
x
|
-1.45
x
|
-2.25
x
|
-1.62
x
|
-2.05
x
|
-2.86
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
150
x
|
29.1
x
|
5.06
x
|
4.61
x
|
2.4
x
|
1.25
x
|
0.77
x
|
EV / Revenue
|
-
|
150
x
|
29.1
x
|
5.06
x
|
4.61
x
|
2.4
x
|
1.25
x
|
0.77
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-45,875,974
x
|
-
|
-1,278,349
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,483
|
6,939
|
7,475
|
8,306
|
10,337
|
12,450
|
-
|
-
|
Reference price
2 |
12.15
|
100.6
|
26.55
|
4.989
|
4.080
|
2.100
|
2.100
|
2.100
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/23/22
|
3/22/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4.651
|
6.812
|
8.184
|
9.154
|
10.89
|
20.9
|
34.01
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-17.98
|
-
|
-32.76
|
-18.85
|
-17.57
|
-14.12
|
-8.989
|
Operating Margin
|
-
|
-386.61%
|
-
|
-400.35%
|
-205.94%
|
-161.32%
|
-67.56%
|
-26.43%
|
Earnings before Tax (EBT)
1 |
-
|
-17.9
|
-
|
-27.17
|
-16.69
|
-16.9
|
-12
|
-7.4
|
Net income
1 |
-15.24
|
-17.9
|
-
|
-27.17
|
-16.69
|
-17.09
|
-15.15
|
-9.974
|
Net margin
|
-
|
-384.97%
|
-
|
-331.99%
|
-182.32%
|
-156.85%
|
-72.5%
|
-29.33%
|
EPS
2 |
-2.700
|
-2.700
|
-4.200
|
-3.450
|
-1.810
|
-1.300
|
-1.027
|
-0.7350
|
Free Cash Flow
|
-
|
-15.22
|
-
|
-32.42
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-327.33%
|
-
|
-396.1%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/23/22
|
3/22/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.851
|
1.893
|
-
|
2.072
|
2.153
|
2.316
|
2.491
|
2.217
|
2.13
|
2.153
|
2.6
|
2.895
|
3.189
|
4
|
4.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-9.247
|
-
|
-9.697
|
-5.601
|
-5.769
|
-4.321
|
-4.116
|
-4.135
|
-4.71
|
-4.184
|
-4.4
|
-4.444
|
-
|
-
|
Operating Margin
|
-
|
-488.48%
|
-
|
-468%
|
-260.15%
|
-249.09%
|
-173.46%
|
-185.66%
|
-194.13%
|
-218.76%
|
-160.92%
|
-151.97%
|
-139.32%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-9.268
|
-
|
-4.558
|
-5.101
|
-6.067
|
-2.317
|
-4.706
|
-3.089
|
-4.629
|
-4
|
-4.2
|
-4.1
|
-
|
-
|
Net income
1 |
-
|
-9.268
|
-8.243
|
-4.558
|
-5.101
|
-6.067
|
-2.317
|
-4.706
|
-3.089
|
-4.629
|
-4
|
-4.2
|
-4.1
|
-
|
-
|
Net margin
|
-
|
-489.59%
|
-
|
-219.98%
|
-236.93%
|
-261.96%
|
-93.01%
|
-212.27%
|
-145.02%
|
-215%
|
-153.85%
|
-145.08%
|
-128.55%
|
-
|
-
|
EPS
2 |
-1.200
|
-1.200
|
-1.050
|
-0.6000
|
-0.6000
|
-0.7300
|
-0.2800
|
-0.4800
|
-0.3000
|
-0.3900
|
-0.3050
|
-0.2700
|
-0.2350
|
-0.2300
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/22/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/28/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-15.2
|
-
|
-32.4
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.49
|
-
|
0.23
|
-
|
0.03
|
0.03
|
0.03
|
Capex / Sales
|
-
|
10.54%
|
-
|
2.83%
|
-
|
0.23%
|
0.12%
|
0.07%
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/23/22
|
3/22/23
|
3/28/24
|
-
|
-
|
-
|
Average target price
5.25
USD Spread / Average Target +150.02% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.53% | 26.14M | | -41.97% | 7.92B | | +5.99% | 3.51B | | -4.31% | 2.18B | | -21.69% | 1.97B | | -24.94% | 1.58B | | +31.45% | 1.14B | | +26.75% | 792M | | -9.83% | 690M | | -26.33% | 532M |
Bio Diagnostics & Testing
|